AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data

AcelRx Pharmaceuticals (Nasdaq: ACRX ) today presented additional detail from the Phase 2 dose-finding study of ARX-04, an investigational single-dose sublingual sufentanil NanoTab for moderate-to-severe acute pain, for which topline results were reported in April 2013. Patients treated with the 30 mcg dose of sufentanil showed a rapid onset